The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...

Only 15% of those who start a glucagon-like peptide 1 (GLP-1) for weight loss are still taking it two years according to ...

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the FDA revisits its decision to remove it.

Millions of Americans rely on a new class of medications to manage chronic conditions like diabetes and obesity, with ...

A trial, targeted at people living with obesity from Britain to Puerto Rico, is the first head-to-head comparison of the ...

The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

You’ve probably heard of the semaglutide brand names Ozempic®, Wegovy, and Rybelsus. You may have even heard about affordable options like compounded semaglutide.

Those who took Ozempic or a similar drug had a 40% lower chance of overdosing on opioids and a 50% lower chance of getting ...

Researchers estimate that expanding access to weight-loss drugs could save over 50,000 lives annually, reducing obesity rates ...

The Alliance for Pharmacy Compounding (APC) wants clarity around the FDA’s decision to reconsider tirzepatide’s removal from ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...